Edoxaban
Oral Factor Xa inhibitor — FDA approved 2015. Latest of the antistasin-inspired DOAC class.
Mechanistic Evidence Box
Studied off-label- Page type
- Compound profile
- Evidence type
- Oral Factor Xa inhibitor — FDA approved 2015. Latest of the antistasin-inspired DOAC class.
- Evidence level
- FDA-cleared regulatory context
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
Edoxaban is a chemically synthesized small-molecule Factor Xa inhibitor; it shares only the molecular target with leech antistasin and is not structurally derived from it. Its RCT evidence base (ENGAGE AF-TIMI 48) applies only to the drug, not to whole medicinal-leech therapy.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Tier A — FDA-approved derivative
- Molecular weight
- 548.06 Da
- Source species
- Synthetic
- Discovered
- 2011 · Daiichi Sankyo
- PubChem CID
- 10280735
- Derived FDA-approved drug
- Savaysa / Lixiana (FDA approved Jan 2015)
Biological Targets
- → Factor Xa
Key Citations
- Giugliano RP et al. (ENGAGE AF-TIMI 48) (2013), N Engl J Med · PMID 24251359
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.